BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 15225502)

  • 1. [The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis].
    Tomás M; Latorre G; Sentí M; Marrugat J
    Rev Esp Cardiol; 2004 Jun; 57(6):557-69. PubMed ID: 15225502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important?
    Mackness M; Mackness B
    Free Radic Biol Med; 2004 Nov; 37(9):1317-23. PubMed ID: 15454272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes.
    Rosenblat M; Karry R; Aviram M
    Atherosclerosis; 2006 Jul; 187(1):74-81. PubMed ID: 16229851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
    Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
    Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variation in paraoxonase-1 activity and atherosclerosis.
    Soran H; Younis NN; Charlton-Menys V; Durrington P
    Curr Opin Lipidol; 2009 Aug; 20(4):265-74. PubMed ID: 19550323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidative stress and high-density lipoprotein function in Type I diabetes and end-stage renal disease.
    Kalogerakis G; Baker AM; Christov S; Rowley KG; Dwyer K; Winterbourn C; Best JD; Jenkins AJ
    Clin Sci (Lond); 2005 Jun; 108(6):497-506. PubMed ID: 15634192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PON1 status is influenced by oxidative stress and inflammation in coronary heart disease patients.
    Kotur-Stevuljevic J; Spasic S; Jelic-Ivanovic Z; Spasojevic-Kalimanovska V; Stefanovic A; Vujovic A; Memon L; Kalimanovska-Ostric D
    Clin Biochem; 2008 Sep; 41(13):1067-73. PubMed ID: 18634772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity.
    James RW; Deakin SP
    Free Radic Biol Med; 2004 Dec; 37(12):1986-94. PubMed ID: 15544917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1.
    Deakin SP; James RW
    Clin Sci (Lond); 2004 Nov; 107(5):435-47. PubMed ID: 15265000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks.
    Sumegová K; Blazícek P; Waczulíková I; Zitnanová I; Duracková Z
    Acta Biochim Pol; 2006; 53(4):783-7. PubMed ID: 17106515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of oxidative stress and PON1 with LDL and HDL particle size in middle-aged subjects.
    Vekic J; Kotur-Stevuljevic J; Jelic-Ivanovic Z; Spasic S; Spasojevic-Kalimanovska V; Topic A; Zeljkovic A; Stefanovic A; Zunic G
    Eur J Clin Invest; 2007 Sep; 37(9):715-23. PubMed ID: 17696961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-density lipoproteins, inflammation and oxidative stress.
    Tabet F; Rye KA
    Clin Sci (Lond); 2009 Jan; 116(2):87-98. PubMed ID: 19076062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of paraoxonase (PON1) activity.
    Costa LG; Vitalone A; Cole TB; Furlong CE
    Biochem Pharmacol; 2005 Feb; 69(4):541-50. PubMed ID: 15670573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidative inactivation of paraoxonase1, an antioxidant protein and its effect on antioxidant action.
    Nguyen SD; Sok DE
    Free Radic Res; 2003 Dec; 37(12):1319-30. PubMed ID: 14753756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paraoxonases role in the prevention of cardiovascular diseases.
    Rosenblat M; Aviram M
    Biofactors; 2009; 35(1):98-104. PubMed ID: 19319852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease.
    Moradi H; Pahl MV; Elahimehr R; Vaziri ND
    Transl Res; 2009 Feb; 153(2):77-85. PubMed ID: 19138652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S-Glutathionylation regulates HDL-associated paraoxonase 1 (PON1) activity.
    Rozenberg O; Aviram M
    Biochem Biophys Res Commun; 2006 Dec; 351(2):492-8. PubMed ID: 17070779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of homocysteine-thiolactonase activity of the paraoxonase-1 (PON1) protein in humans.
    Lacinski M; Skorupski W; Cieslinski A; Sokolowska J; Trzeciak WH; Jakubowski H
    Cell Mol Biol (Noisy-le-grand); 2004 Dec; 50(8):885-93. PubMed ID: 15704252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effect of paraoxonase 1 of high-density lipoprotein in type 2 diabetic patients with nephropathy.
    Li C; Gu Q
    Nephrology (Carlton); 2009 Aug; 14(5):514-20. PubMed ID: 19207863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The correlation of homocysteine-thiolactonase activity of the paraoxonase (PON1) protein with coronary heart disease status.
    Domagała TB; Łacinski M; Trzeciak WH; Mackness B; Mackness MI; Jakubowski H
    Cell Mol Biol (Noisy-le-grand); 2006 Dec; 52(5):4-10. PubMed ID: 17543199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.